Last reviewed · How we verify

Estetra — Portfolio Competitive Intelligence Brief

Estetra pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
VAL VAL marketed Nucleoside analog antiviral Cytomegalovirus (CMV) DNA polymerase Infectious Disease / Virology
Estetrol oral tablet Estetrol oral tablet phase 3 Selective estrogen receptor modulator (SERM) Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) Gynecology / Contraception / Women's Health

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  2. AstraZeneca · 1 shared drug class
  3. Austrian Breast & Colorectal Cancer Study Group · 1 shared drug class
  4. French National Agency for Research on AIDS and Viral Hepatitis · 1 shared drug class
  5. Fundació Privada Eugin · 1 shared drug class
  6. Göteborg University · 1 shared drug class
  7. H. Lee Moffitt Cancer Center and Research Institute · 1 shared drug class
  8. Ain Shams University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Estetra:

Cite this brief

Drug Landscape (2026). Estetra — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/estetra. Accessed 2026-05-14.

Related